Dr. Scott Dindot

Dr. Dindot, an associate professor in the Texas A&M School of Veterinary Medicine & Biomedical Sciences’ Department of Veterinary Pathobiology and in the School of Medicine’s Department of Molecular & Cellular Medicine. Dr. Dindot’s lab is interested in understanding the molecular, genetic and epigenetic mechanisms underlying phenotypic variation and disease. They use multifaceted genetic, molecular and cell biological tools as well as genetically engineered model organisms and domestic animal models to understand the interplay between genetics, epigenetics and gene regulation. Their lab further investigates how each modulates phenotypes in some situations and causes disease in others. There are two major areas of research interest in his laboratory. First, they are investigating the epigenetic mechanisms regulating genomic imprinting, including diseases and phenotypes associated with imprinted genes. Second, they are investigating genomic structural variants and their role in phenotypic variation and disease. Dr. Dindot developed the pig model for Angelman’s syndrome. And, has developed a targeted drug therapy now known as GTX-102. His drug therapy was the subject of a $75 million acquisition by Ultragenyx Pharmaceutical, Inc., which is leading the continued development of the treatment.